Literature DB >> 27411552

Comparison of 1800 Robotic and Open Partial Nephrectomies for Renal Tumors.

Benoit Peyronnet1, Thomas Seisen2, Emmanuel Oger3, Christophe Vaessen2, Yohann Grassano4, Thibaut Benoit5, Julie Carrouget6, Benjamin Pradère7, Zineddine Khene7, Anthony Giwerc8, Romain Mathieu7, Jean-Baptiste Beauval5, François-Xavier Nouhaud8, Pierre Bigot6, Nicolas Doumerc5, Jean-Christophe Bernhard4, Arnaud Mejean9, Jean-Jacques Patard10, Sharokh Shariat11, Morgan Roupret2, Karim Bensalah7.   

Abstract

BACKGROUND: Only a few studies have compared the outcomes of robotic partial nephrectomy (RPN) and open partial nephrectomy (OPN). This study aimed to compare perioperative and oncologic outcomes of RPN and OPN.
METHODS: The data of all patients who underwent partial nephrectomy from 2006 to 2014 in six academic departments of urology were retrospectively collected. Perioperative outcomes were compared between OPN and RPN patients. Cancer-specific survival (CSS) and recurrence-free survival (RFS) were estimated using the Kaplan-Meier method and compared using the log-rank test.
RESULTS: The study included 1800 patients: 937 who underwent RPN and 863 who underwent OPN. The patients in the robotic group had smaller tumors (33.1 vs. 39.9 mm; p < 0.001) but comparable RENAL scores (6.8 vs. 6.7; p = 0.37). The complication rate was higher in the OPN group (28.6 vs. 18 %; p < 0.001). The OPN patients had greater estimated blood loss (359.5 vs. 275 ml; p < 0.001) and more frequent hemorrhagic complications (12.1 vs. 6.9 %; p < 0.001). The robotic approach was associated with a shorter warm ischemia time (WIT 15.7 vs. 18.6 min; p < 0.001) and a shorter hospital of stay (4.7 vs. 10.1 days; p < 0.001). In the propensity score-weighted analysis, the inverse probability of treatment weighting adjusted odds ratio for the risk of complication after OPN versus RPN was 2.11 (95 % confidence interval, 1.53-2.91; p < 0.001). After a median postoperative follow-up period of 13 months for OPN and 39 months for RPN (p < 0.001), CSS and RFS were similar in the two groups. In the multivariate analysis, RPN showed an impact on the occurrence of a complication but had no effect on WIT or RFS.
CONCLUSION: In this study, RPN was less morbid than OPN, with lower complications, less blood loss, and a shorter hospital of stay. The intermediate-term oncologic outcomes were similar in the two groups.

Entities:  

Mesh:

Year:  2016        PMID: 27411552     DOI: 10.1245/s10434-016-5411-0

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  16 in total

1.  Long-term oncological outcomes after robotic partial nephrectomy for renal cell carcinoma: a prospective multicentre study.

Authors:  Jean-Baptiste Beauval; Benoit Peyronnet; Thibaut Benoit; Bastien Cabarrou; Thomas Seisen; Mathieu Roumiguié; Benjamin Pradere; Zine-Eddine Khene; Quentin Manach; Gregory Verhoest; Mathieu Thoulouzan; Jerome Parra; Nicolas Doumerc; Romain Mathieu; Christophe Vaessen; Michel Soulié; Morgan Roupret; Karim Bensalah
Journal:  World J Urol       Date:  2018-02-09       Impact factor: 4.226

2.  Perioperative Morbidity of Open Versus Minimally Invasive Partial Nephrectomy: A Contemporary Analysis of the National Surgical Quality Improvement Program.

Authors:  Jorge Pereira; Joseph Renzulli; Gyan Pareek; Daniel Moreira; Ruiting Guo; Zheng Zhang; Ali Amin; Anthony Mega; Dragan Golijanin; Boris Gershman
Journal:  J Endourol       Date:  2017-12-21       Impact factor: 2.942

3.  Single-port robotic-assisted partial nephrectomy: initial clinical experience and lessons learned for successful outcomes.

Authors:  Devki Shukla; Alexander Small; Reza Mehrazin; Michael Palese
Journal:  J Robot Surg       Date:  2020-06-20

4.  Nurse-led coordinated surgical care pathways for cost optimization of robotic-assisted partial nephrectomy: medico-economic analysis of the UroCCR-25 AMBU-REIN study.

Authors:  Jean-Christophe Bernhard; Grégoire Robert; Solène Ricard; Julien Rogier; Cécile Degryse; Clément Michiels; Gaëlle Margue; Peggy Blanc; Eric Alezra; Vincent Estrade; Grégoire Capon; Franck Bladou; Jean-Marie Ferriere
Journal:  World J Urol       Date:  2022-06-21       Impact factor: 4.226

Review 5.  Diagnosis and Treatment of Small Renal Masses: Where Do We Stand?

Authors:  Jerez Izquierdo Tamara; Gómez Rivas Juan; Zondervan Jeannelle Patricia; Vives Dilme Roser; Rodriguez Moisés; Enikeev Dmitry; Serrano Pascual Álvaro; Moreno Sierra Jesús
Journal:  Curr Urol Rep       Date:  2022-05-04       Impact factor: 3.092

6.  Comparison of survival and renal function between partial and radical laparoscopic nephrectomy for T1b renal cell carcinoma.

Authors:  Feiya Yang; Qiang Zhou; Nianzeng Xing
Journal:  J Cancer Res Clin Oncol       Date:  2019-11-01       Impact factor: 4.553

7.  Kidney ventrally rotation technique in retroperitoneal robot-assisted partial nephrectomy for posterior hilar tumor: technical feasibility and preliminary results.

Authors:  Xiaotao Yin; Sinan Jiang; Zhiqiang Shao; Yongliang Lu; Jiaxiang Guo; Yi Xiao; Xiaoying Zhu; Hualiang Yu; Han Ma; Yu Yang; Jiangping Gao
Journal:  World J Surg Oncol       Date:  2020-06-30       Impact factor: 2.754

8.  Operative outcomes of robotic partial nephrectomy. A report of the first 101 cases from a single center in Saudi Arabia.

Authors:  Raouf M Seyam; Mohammed M Alalawi; Waleed K Alkhudair; Hassan M Alzahrani; Raed A Azhar; Khalid I Alothman; Turki O Al-Hussain; Mohammed F Alotaibi
Journal:  Saudi Med J       Date:  2019-01       Impact factor: 1.484

9.  Performing all major surgical procedures robotically will prolong wait times for surgery.

Authors:  Brian M Shinder; Nicholas J Farber; Robert E Weiss; Thomas L Jang; Isaac Y Kim; Eric A Singer; Sammy E Elsamra
Journal:  Robot Surg       Date:  2017-08-17

Review 10.  Complications in robotic urological surgeries and how to avoid them: A systematic review.

Authors:  Rafael Rocha Tourinho-Barbosa; Marcos Tobias-Machado; Adalberto Castro-Alfaro; Gabriel Ogaya-Pinies; Xavier Cathelineau; Rafael Sanchez-Salas
Journal:  Arab J Urol       Date:  2017-12-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.